State Street Corp Boosts Stock Position in Zoetis Inc. $ZTS

Key Points

• State Street increased its Zoetis stake by 1.8% in the second quarter, adding 343,322 shares to own 19.67 million shares valued at approximately $1.41 billion. Institutional investors collectively hold 92.8% of Zoetis stock.
• Zoetis reported quarterly EPS of $1.87, topping estimates of $1.85, while revenue of $2.47 billion fell slightly short of expectations and declined 0.2% year over year. The company issued fiscal 2026 EPS guidance of $6.15–$6.25.
• Analyst sentiment is mixed, with a consensus “Hold” rating and an average price target of $101.08. Zoetis shares opened at $72.76, close to their one-year low of $70.26.

State Street Corp increased its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 1.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,667,723 shares of the company's stock after buying an additional 343,322 shares during the period. State Street Corp owned about 4.76% of Zoetis worth $1,413,323,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently added to or reduced their stakes in the company. Tidal Investments LLC increased its stake in shares of Zoetis by 22.8% during the second quarter. Tidal Investments LLC now owns 493,507 shares of the company's stock worth $35,463,000 after purchasing an additional 91,492 shares in the last quarter. National Pension Service grew its position in shares of Zoetis by 9.6% in the second quarter. National Pension Service now owns 839,875 shares of the company's stock valued at $60,353,000 after purchasing an additional 73,785 shares in the last quarter. WINTON GROUP Ltd acquired a new stake in shares of Zoetis in the second quarter valued at approximately $223,000. Engineers Gate Manager LP increased its holdings in shares of Zoetis by 3,551.3% in the second quarter. Engineers Gate Manager LP now owns 107,678 shares of the company's stock valued at $7,738,000 after purchasing an additional 104,729 shares during the last quarter. Finally, SVB Wealth LLC lifted its position in Zoetis by 14.3% during the second quarter. SVB Wealth LLC now owns 27,385 shares of the company's stock worth $1,968,000 after buying an additional 3,426 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Zoetis Trading Up 2.0%

Shares of ZTS stock opened at $72.76 on Wednesday. The business's fifty day moving average price is $75.20 and its 200 day moving average price is $88.98. The firm has a market capitalization of $30.07 billion, a PE ratio of 11.99, a P/E/G ratio of 1.66 and a beta of 0.73. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84. Zoetis Inc. has a 1-year low of $70.26 and a 1-year high of $148.79.

Zoetis (NYSE:ZTS - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, topping the consensus estimate of $1.85 by $0.02. The company had revenue of $2.47 billion for the quarter, compared to analyst estimates of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The business's revenue was down .2% on a year-over-year basis. During the same period in the previous year, the firm earned $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, sell-side analysts forecast that Zoetis Inc. will post 6.2 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ZTS has been the subject of several analyst reports. William Blair restated a "market perform" rating on shares of Zoetis in a report on Thursday, August 6th. Argus reaffirmed a "hold" rating on shares of Zoetis in a research note on Wednesday, May 27th. UBS Group decreased their price objective on Zoetis from $85.00 to $80.00 and set a "neutral" rating for the company in a research note on Friday, August 7th. TD Cowen cut their price objective on shares of Zoetis from $104.00 to $94.00 and set a "buy" rating on the stock in a report on Tuesday, August 25th. Finally, Piper Sandler reduced their price objective on Zoetis from $90.00 to $80.00 and set a "neutral" rating for the company in a research note on Monday, August 10th. Eight research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $101.08.

Zoetis Company Profile

Zoetis Inc is a global animal health company that develops, manufactures and commercializes medicines, vaccines, diagnostic products and related services for livestock and companion animals. Its offerings are used by veterinarians, livestock producers and pet owners to prevent and treat disease, improve animal health and support productivity.

The company's product portfolio includes pharmaceuticals, vaccines, parasiticides, dermatology treatments, diagnostic tests and genetic services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.